Coordinación científica: Dr. Fernando Rivera Hospital Universitario Marqués de Valdecilla, Santander Organizado por: Fundación para el progreso de la oncología en Cantabria Novedades quirúrgicas en cáncer de ovario Sergio Martínez Román Director clínico territorial y jefe de servicio de Ginecología Hospital Universitario Germans Trias I Pujol, Badalona
87
Embed
¿ Qué aporta la cirugía - oncopromesas-oncosaurios.com · Peritonitis Recto-vaginal fistula Careful technique. Tension-free anastomosis Intraoperative air leak test Discretional
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Coordinación científica:Dr. Fernando RiveraHospital Universitario Marqués de Valdecilla,
Santander
Organizado por: Fundación para el progreso
de la oncología en Cantabria
Novedades quirúrgicas en cáncer de ovarioSergio Martínez Román
Director clínico territorial y jefe de servicio de Ginecología
Hospital Universitario Germans Trias I Pujol, Badalona
Disclosure
Yo hice E.G.B.
¿ Qué aporta la cirugía ?
Cytoreductive surgery: a different oncologic
surgery
• Joe V. Meigs MD, 1934
• Mass. Gen. Hosp. US
“enhance the effects of radiation therapy”
Biologic rationale for cytoreduction
• Goldie y Coldman mathematical model (Cancer Treat Rep, 1979)
– Definition: a mathematic model that predicts that tumor cells mutate to a resistant phenotype at a rate dependent on their intrinsic genetic instability.
– “The probability that a cancer would contain drug-resistant clones depends onthe mutation rate and the size of the tumor.”
quimioresistenciaquimioterápia
Primaria Adquirida
The role of the surgical effort. 8.674 pt
68
4033
81
35 30
72
37 33
78
50
36
86
4637
110
54
0
20
40
60
80
100
120
MICROSCOPIC < 1 CM >1 CM
SU
RV
IV
AL M
ON
TH
S
MINIMAL RESIDUAL DISEASE AFTER DEBULKING
BOOKMAN DUBOIS QUERLEU CHI CHANG IP LANDRUM
PRIMARY DEBULKINGSTAGES IIIC-IV
72 MONTHS
44MONTHS
32MONTHS
Cortesía Dr. Luis Chiva
5-year survival rate
du Bois A, Reuss A, Pujade-Lauraine E, et al. Cancer 2009;15:1234–44
The impact of residual tumour on outcome in advanced ovarian cancerData from an individual patient meta-analysis of three randomised phase III trials with 3,126 patients
log-rank: p<0.0001
0%
25%
50%
75%
100%
0 12 24 36 48 60 72 84 96 108 120 132 144
Ove
rall
surv
ival
(%
)
0mm
1–10mm>10mm
Time (months)
5-year survival rate
du Bois A, Reuss A, Pujade-Lauraine E, et al. Cancer 2009;15:1234–44
The impact of residual tumour on outcome in advanced ovarian cancerData from an individual patient meta-analysis of three randomised phase III trials with 3,126 patients
log-rank: p<0.0001
0%
25%
50%
75%
100%
0 12 24 36 48 60 72 84 96 108 120 132 144
Ove
rall
surv
ival
(%
)
0mm
1–10mm>10mm
Time (months)
2 %
Defining cohorts
according to potential
benefit from surgery
5-year survival rate
du Bois A, Reuss A, Pujade-Lauraine E, et al. Cancer 2009;15:1234–44
The impact of residual tumour on outcome in advanced ovarian cancerData from an individual patient meta-analysis of three randomised phase III trials with 3,126 patients
log-rank: p<0.0001
0%
25%
50%
75%
100%
0 12 24 36 48 60 72 84 96 108 120 132 144
Ove
rall
surv
ival
(%
)
0mm
1–10mm>10mm
Time (months)
2 %2 %
33 %
Defining cohorts
according to potential
benefit of surgery
5-year survival rate
du Bois A, Reuss A, Pujade-Lauraine E, et al. Cancer 2009;15:1234–44
The impact of residual tumour on outcome in advanced ovarian cancerData from an individual patient meta-analysis of three randomised phase III trials with 3,126 patients
log-rank: p<0.0001
0%
25%
50%
75%
100%
0 12 24 36 48 60 72 84 96 108 120 132 144
Ove
rall
surv
ival
(%
)
0mm
1–10mm>10mm
Time (months)
2 %2 %
33 %
60 %
Defining cohorts
according to potential
benefit of surgery
5-year survival rate
du Bois A, Reuss A, Pujade-Lauraine E, et al. Cancer 2009;15:1234–44
The impact of residual tumour on outcome in advanced ovarian cancerData from an individual patient meta-analysis of three randomised phase III trials with 3,126 patients
log-rank: p<0.0001
0%
25%
50%
75%
100%
0 12 24 36 48 60 72 84 96 108 120 132 144
Ove
rall
surv
ival
(%
)
0mm
1–10mm>10mm
Time (months)
2 %
2 %2 %
33 %
60 %
Defining cohorts
according to potential
benefit of surgery
¿A quién y cuando?
OPERATE OR NOT?
PATIENT
Operability
DISEASE
Resectability
SURGICAL TEAM
Performance
Aletti criteria
Age≥75 years
PS (ASA)/Nutritional (albumin ≤3)
Stage IV/extensive surgery
¿Podemos predecir la resecabilidad
antes de ir a quirófano?
• Rule out extraabdominal disease
• Number, size, anatomical relationships
• Estimation of resectability
FDG-glucose PET-CT
Valoración temprana respuesta a neoadyuvancia
Molecular Imaging
Marcaje de dianas moleculares sobreexpresadas en
células tumorales
• Estadificación no invasiva
• Cirugía radioguiada
• Biomarcadores predictivos
• Monitorización de respuesta terapéutica
Introperative PET probes• Radioguided surgery
No FDG PET imaging
• Síntesis de DNA: 18F-fluorodeoxitimidina (18F-FLT)